Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
|Articles|July 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 7
- Volume 15
- Issue 7
Phase III Trial of Enzastaurin for NHL Patients Initiated
Phase III Trial of Enzastaurin for NHL Patients Initiated
Advertisement
INDIANAPOLISEli Lilly has initiated a randomized, placebo- controlled phase III trial of its experimental agent enzastaurin as maintenance therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL) who have achieved remission after first-line therapy. In early clinical studies, enzastaurin, an oral serinethreonine kinase inhibitor, showed promising activity in NHL.
Articles in this issue
over 20 years ago
High-Quality Screening Colonoscopy Priority for GI Docsover 20 years ago
Genentech Seeks Expanded Use of Avastin in Breast Cancerover 20 years ago
Denosumab Suppresses Bone Resorption in Breast Ca Metsover 20 years ago
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)over 20 years ago
FDA Approves Revlimid for Myeloma Rxover 20 years ago
Real-Time RT Planning, Delivery in the Bronxover 20 years ago
Racial Disparities in Prostate Ca Recurrenceover 20 years ago
HNPCC Pts May Reject Prophylactic Subtotal ColectomyAdvertisement
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5